Everolimus 5mg Everolimus tablets 5mg x 30 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Non-infectious pneumonia: Monitor for clinical symptoms or radiological changes. Discontinuation or permanent discontinuation depending on the severity.
• Infection: Monitor for signs and symptoms of infection. Discontinuation or permanent discontinuation depending on the severity.
• Severe hypersensitivity reaction: permanently discontinue in case of clinically significant hypersensitivity reaction.
• Angioedema: Patients who are also taking angiotensin-converting enzyme (ACE) inhibitors may have an increased risk of angioedema. In case of angioedema, permanently discontinue.
• Stomatitis: Dexamethasone non-alcoholic mouthwash should be used when starting treatment.
• Renal failure: regular monitoring of renal function before and after treatment.
• Risk of poor wound healing: discontinuation at least 1 week prior to elective surgery. Do not use this product for at least 2 weeks after major surgery until the wound has fully healed. The safety of recovery therapy after resolution of wound healing complications has not been determined.
• Elderly patients: monitor for adverse reactions and adjust dose.
• Metabolic disorders: Regular monitoring of blood glucose and lipids before and after treatment. Discontinuation or permanent discontinuation is determined by the severity of the condition.
• Myelosuppression: Hematological parameters are regularly monitored before and after treatment. Discontinuation or permanent discontinuation is determined by the severity of the condition.
• Vaccination risk of infection or reduced risk of immune response: Avoid live vaccination and avoid close contact with people who have been vaccinated. Complete the recommended childhood vaccinations before starting treatment.
• Radiosensitization and radiological recall: Serious radiological reactions may occur.
• Embryo-fetal toxicity: May cause damage to the fetus. Patients of childbearing potential are advised to be aware of the potential risks to the fetus and to take effective contraceptive measures.

Medication risks

Adverse Reactions
• Breast cancer, neuroendocrine tumors (net), renal cell carcinoma (RCC): The most common adverse reactions (incidence ≥ 30%) include stomatitis, infections, rashes, fatigue, diarrhea, edema, abdominal pain, nausea, pyrexia, asthenia, cough, headache, and decreased appetite.
• Tuberous sclerosis (TSC) -associated renal vascular leiomyolipoma: the most common adverse reaction (incidence ≥ 30%) is stomatitis.
• Tuberous sclerosis (TSC) -associated tremor gastroesophageal reflux (Sega): The most common adverse reactions (incidence ≥ 30%) are stomatitis and respiratory infections.
• Partial epilepsy associated with tuberous sclerosis (TSC): the most common adverse reaction (incidence ≥ 30%) is stomatitis.